HSBC plans to price buffered AMPS linked to SPDR S&P Biotech ETF

By Emma Trincal

New York, Nov. 9 – HSBC USA Inc. plans to price 0% buffered accelerated market participation securities due Nov. 24, 2023 linked to the SPDR S&P Biotech exchange-traded fund, according to an FWP filing with the Securities and Exchange Commission.

If the fund return is positive, the payout at maturity will be par plus 1.5 times the fund gain, subject to a maximum return of at least 29.9% to be set at pricing.

Investors will receive par if the fund falls by 15% or less and will lose 1% for every 1% decline beyond the 15% buffer.

HSBC USA Inc. is the agent.

The notes will price on Nov. 19 and settle on Nov. 24.

The Cusip number is 40438CZK0.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.